STOKELY DAN 4
4 · Ampio Pharmaceuticals, Inc. · Filed Feb 17, 2021
Insider Transaction Report
Form 4
STOKELY DAN
CFO
Transactions
- Exercise/Conversion
Common Stock
2021-02-12$2.55/sh+10,500$26,775→ 52,500 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-12−42,000→ 358,000 totalExercise: $0.43Exp: 2029-08-20→ Common Stock (42,000 underlying) - Exercise/Conversion
Common Stock
2021-02-12$2.55/sh+42,000$107,100→ 42,000 total - Tax Payment
Common Stock
2021-02-12$2.55/sh−24,185$61,672→ 28,315 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-12−10,500→ 19,500 totalExercise: $0.59Exp: 2030-01-02→ Common Stock (10,500 underlying)
Footnotes (3)
- [F1]The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 23, 2020.
- [F2]Options were granted and previously reported on a Form 4 dated August 22, 2019, where 50% of the stock option award vested and became exerciserable on the date of the August 20, 2019 grant and the remaining 50% of the stock option award vested and became exerciserable on July 31, 2020.
- [F3]Options were granted and previously reported on a Form 4 dated January 6, 2020, where 50% of the option award vested and became exercisable on the January 2, 2020 date of the grant and the remaining 50% of the option award vested and became exercisable on July 31, 2020.